Real-World Immunosuppressant Treatment Patterns in Lupus Nephritis: A Retrospective Claims Database Analysis in the United States (ACR Convergence 2025) - Sep 15, 2025 - Abstract #1038; Pres time: Oct 27, 2025; 10:30 AM - 12:30 PM; Location: Hall F1; In Person; "We aimed to characterize real-world treatment patterns in newly diagnosed patients with LN within the United States (US), focusing on use of immunosuppressants (ISTs) and advanced therapies including belimumab and voclosporin. This retrospective cohort study utilized US healthcare claims data from the IQVIA PharMetrics® Plus database from January 1, 2017 to December 31, 2023...Of these, 946 patients (48%) received an IST as their first LoT, primarily mycophenolate mofetil (MMF, 66%), azathioprine (AZA, 10%) and/or belimumab (6%)... This health insurance claims-based study identified diverse treatment use in newly diagnosed patients with LN, with nearly half receiving an IST in the first LoT. Variability in treatment duration and regimens reflects dynamic patient needs and treatment practices. Understanding these patterns is essential for optimizing LN care and informing future monitoring of treatment changes following practice guideline updates and..."
Claims database • Real-world • Real-world evidence • Retrospective data • Glomerulonephritis • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Cell Carcinoma • Renal Disease • Respiratory Diseases • Tuberculosis
|
|
Anisha Patel1; Alexandra Miller1; Lisa Lindsay1; Danny Sheinson1; Zhiyu Xia1; William Pendergraft1; Maria Dall'Era2
|